Cargando…
Clinical use of Bevacizumab in treating refractory glaucoma
Bevacizumab is a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). Though other VEGF inhibitors are being approved for the treatment of ophthalmological conditions, bevacizumab found its way into ophthalmology and clinical practice all around the w...
Autores principales: | Popescu, V, Pricopie, S, Totir, M, Iancu, R, Yasyn, S, Alexandrescu, C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397528/ https://www.ncbi.nlm.nih.gov/pubmed/25914729 |
Ejemplares similares
-
The efficiency of subconjunctival bevacizumab in refractory glaucoma - case report
por: Popescu, V, et al.
Publicado: (2015) -
Topographic measurements of eyelids and orbit in enucleated eyes with hydroxyapatite integrated implant versus PMMA implant
por: Gradinaru, S, et al.
Publicado: (2014) -
Clinical, Histopathological and Therapeutical Analysis of Inferior
Eyelid Basal Cell Carcinomas
por: Totir, M, et al.
Publicado: (2014) -
Subconjunctival Bevacizumab as an Adjunct to Trabeculectomy in Eyes with Refractory Glaucoma: A Case Series
por: Choi, Jin Young, et al.
Publicado: (2010) -
Intravitreal bevacizumab as therapy for refractory neovascular glaucoma secondary to iris metastasis of breast carcinoma
por: Vale, Stephanie, et al.
Publicado: (2018)